Your browser doesn't support javascript.
loading
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma.
Coffman, Lan G; Pearson, Alexander T; Frisbie, Leonard G; Freeman, Zachary; Christie, Elizabeth; Bowtell, David D; Buckanovich, Ronald J.
Afiliación
  • Coffman LG; Division of Hematology Oncology, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Pearson AT; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Frisbie LG; Division of Hematology Oncology, Department of Internal Medicine, University of Chicago, Illinois, USA.
  • Freeman Z; Division of Hematology Oncology, Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Christie E; Unit for Laboratory Animal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.
  • Bowtell DD; Research Division Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
  • Buckanovich RJ; Research Division Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
Stem Cells ; 37(2): 257-269, 2019 02.
Article en En | MEDLINE | ID: mdl-30353617
Carcinoma-associated mesenchymal stem cells (CA-MSCs) are critical stromal progenitor cells within the tumor microenvironment (TME). We previously demonstrated that CA-MSCs differentially express bone morphogenetic protein family members, promote tumor cell growth, increase cancer "stemness," and chemotherapy resistance. Here, we use RNA sequencing of normal omental MSCs and ovarian CA-MSCs to demonstrate global changes in CA-MSC gene expression. Using these expression profiles, we create a unique predictive algorithm to classify CA-MSCs. Our classifier accurately distinguishes normal omental, ovary, and bone marrow MSCs from ovarian cancer CA-MSCs. Suggesting broad applicability, the model correctly classifies pancreatic and endometrial cancer CA-MSCs and distinguishes cancer associated fibroblasts from CA-MSCs. Using this classifier, we definitively demonstrate ovarian CA-MSCs arise from tumor mediated reprograming of local tissue MSCs. Although cancer cells alone cannot induce a CA-MSC phenotype, the in vivo ovarian TME can reprogram omental or ovary MSCs to protumorigenic CA-MSCs (classifier score of >0.96). In vitro studies suggest that both tumor secreted factors and hypoxia are critical to induce the CA-MSC phenotype. Interestingly, although the breast cancer TME can reprogram bone marrow MSCs into CA-MSCs, the ovarian TME cannot, demonstrating for the first time that tumor mediated CA-MSC conversion is tissue and cancer type dependent. Together these findings (a) provide a critical tool to define CA-MSCs and (b) highlight cancer cell influence on distinct normal tissues providing powerful insights into the mechanisms underlying cancer specific metastatic niche formation. Stem Cells 2019;37:257-269.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Stem Cells Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Stem Cells Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido